---
document_datetime: 2023-09-21 21:03:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_en.pdf
document_name: leqvio-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7459698
conversion_datetime: 2025-12-18 10:17:18.9462
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form    | Route of administration   | Immediate packaging        | Content (concentration)   | Pack size                              |
|------------------|-------------------|------------|------------------------|---------------------------|----------------------------|---------------------------|----------------------------------------|
| EU/1/20/1494/001 | Leqvio            | 284 mg     | Solution for injection | Subcutaneous use          | pre-filled syringe (glass) | 1.5 ml (189 mg/ml)        | 1 pre-filled syringe                   |
| EU/1/20/1494/002 | Leqvio            | 284 mg     | Solution for injection | Subcutaneous use          | pre-filled syringe (glass) | 1.5 ml (189 mg/ml)        | 1 pre-filled syringe with needle guard |